Elsevier

Drug Resistance Updates

Volume 14, Issue 1, February 2011, Pages 22-34
Drug Resistance Updates

Drug transporters of platinum-based anticancer agents and their clinical significance

https://doi.org/10.1016/j.drup.2010.12.002Get rights and content

Abstract

Platinum-based drugs are among the most active anticancer agents and are successfully used in a wide variety of human malignancies. However, acquired and/or intrinsic resistance still represent a major limitation. Lately, in particular mechanisms leading to impaired uptake and/or decreased cellular accumulation of platinum compounds have attracted attention. In this review, we focus on the role of active platinum uptake and efflux systems as determinants of platinum sensitivity and -resistance and their contribution to platinum pharmacokinetics (PK) and pharmacodynamics (PD). First, the three mostly used platinum-based anticancer agents as well as the most promising novel platinum compounds in development are put into clinical perspective. Next, we describe the presently known potential platinum transporters – with special emphasis on organic cation transporters (OCTs) – and discuss their role on clinical outcome (i.e. efficacy and adverse events) of platinum-based chemotherapy. In addition, transporter-mediated tumour resistance, the impact of potential platinum transporter-mediated drug–drug interactions, and the role of drug transporters in the renal elimination of platinum compounds are discussed.

Introduction

Platinum-based drugs are among the most active anticancer agents and are used as single agent or in combination with other cytotoxic agents and/or radiation therapy in the management of a broad spectrum of human malignancies, including testicular, ovarian, head and neck, colon, bladder, gastric, and lung cancer (Ardizzoni et al., 2007, Go and Adjei, 1999, Lebwohl and Canetta, 1998, McWhinney et al., 2009, Raymond et al., 1998, Rixe et al., 1996, Zhang et al., 2006). Although most patients initially respond well to platinum-based chemotherapy, a considerable number of patients eventually develop drug resistance and relapse (Kollmannsberger et al., 2006). In spite of many efforts to circumvent platinum resistance and to reduce the toxicity of platinum-containing anticancer regimens, the development of either severe side effects, including nephro-, neuro- and ototoxicity, or clinical resistance, are frequent reasons for treatment discontinuation (Giaccone, 2000, McWhinney et al., 2009).

Platinum resistance is considered multi-factorial and includes both mechanisms that limit the formation of platinum–DNA adducts as well as mechanisms that prevent cell death following drug-induced damage (Table 1) (Shahzad et al., 2009, Brabec and Kasparkova, 2005, Stordal et al., 2007, Borst et al., 2008). Actually, reduced cellular accumulation of platinum either by impaired uptake or increased efflux is often found in cells selected for cisplatin resistance, both in vivo and in vitro, and is generally considered as one of the most consistent characteristics of platinum resistant cells (Gately and Howell, 1993).

Previously, passive diffusion through the cellular lipid bilayer was considered to be the dominant process involved in drug uptake and distribution. However, more recently the concept of carrier mediated and active uptake of commonly prescribed drugs, has become rule rather than exception (Dobson et al., 2009). Compelling evidence for a more prominent role of carrier-mediated uptake is rapidly cumulating in the literature (Dobson and Kell, 2008). Facilitated or active transport systems, as well as passive diffusion, are both relevant for the cellular uptake of platinum drugs (Andrews et al., 1990, Gately and Howell, 1993, Johnson et al., 1998). In addition general drug uptake/efflux systems in the intestine, liver and kidney are increasingly found to be important and may have a major impact on drug disposition and response to platinum-based chemotherapy (Terada and Inui, 2007). Thus, (membrane) transporters of platinum compounds, including solute carriers (SLCs) and in particular organic cation transporters (OCTs) belonging to the SLC22 subfamily, may at least in part, predict the platinum sensitivity/resistance of the tumour, markedly affect critical pharmacokinetic (PK) parameters, and determine the severity of platinum-associated adverse events.

Here we discuss the involvement of drug transporters in platinum uptake, efflux, distribution and (renal) elimination as well as their potential effect on treatment efficacy, on critical PK parameters and on the severity of platinum-associated adverse events. Finally, we assess the clinical relevance of platinum transporter-mediated drug–drug interactions.

Section snippets

Platinum compounds in clinical use

To date, three platinum drugs have been approved for clinical use, i.e. cisplatin (1978), its less toxic analogue carboplatin (1989) and oxaliplatin (2002). Various new generation platinum compounds with different properties have been developed over the years (Kelland, 2007a, Kelland, 2007b, Shah and Dizon, 2009). Some of these are currently evaluated in clinical trials. Especially, those with an improved safety profile, those exhibiting antitumor activity against tumour types resistant to

Platinum transporters and their potential effect on cellular accumulation and resistance

Membrane transporters and channels, collectively known as the transportome, are increasingly recognized as important determinants of tumour cell chemosensitivity and chemoresistance (Huang et al., 2004). Only a limited number of drug transporters, including both influx as well as efflux pumps, have been implicated in the intracellular accumulation of platinum compounds (Table 2) and reviewed by Choi and Kim (2006), Hall et al. (2008). Potential platinum uptake or influx transporters include

Transporter mediated drug–drug interactions and their potential effect on the PK of platinum compounds

Nowadays, polypharmacy is common clinical practice in cancer patients. Co-medication of drugs may influence each other's metabolism, excretion and uptake by so-called drug–drug interactions, which may lead to unintended effects like reduced effectiveness or increased toxicities. Transporter-mediated drug–drug interactions and their potential effects on the PK of anticancer drugs have lately been given particular attention (Kindla et al., 2009, Zhang et al., 2009). Clearly, substrate competition

Renal elimination of platinum compounds

It has been well established that most platinum compounds are predominantly eliminated from the body by glomerular filtration in the kidney. During their renal elimination, platinum drugs rely on active facilitated transport rather than passive diffusion across cellular membranes. The most relevant human platinum transporters known to date that are predominantly expressed in the kidney are SLC22A2 and SLC47A1/A2 (Koepsell et al., 2007, Terada and Inui, 2008). Renal tubular secretion of platinum

Platinum transporter-mediated side effects

The occurrence of adverse events from pharmacotherapy depends on many different factors including disease state, inherited disorders, PK characteristics of the drug, unintended drug–drug interactions, differences in drug metabolizing enzymes, transporter activity and renal clearance, and genomic variation in these absorption, disposition, metabolism and excretion (ADME) processes-associated genes. Serious side effects of anticancer platinum compounds have been reported and the possible

Future perspectives

Future developments in platinum-containing chemotherapeutic regimens will focus on novel delivery mechanisms with emphasis on improving the uptake and proper distribution of the existing platinum drugs by e.g. liposomal formulation of cisplatin-like drugs or by binding the platinum compounds to physiological (carrier) proteins to enhance their uptake. Knowledge of the involvement of platinum transporters may be exploited to develop appropriate intervention schedules. For instance, clinical

Acknowledgements

We gratefully thank Peter de Bruijn for preparing the chemical structures of the platinum compound using ChemWin as presented in Fig. 1.

References (128)

  • Y.H. Kim et al.

    Expression of breast cancer resistance protein is associated with a poor clinical outcome in patients with small-cell lung cancer

    Lung Cancer

    (2009)
  • D. Lebwohl et al.

    Clinical development of platinum complexes in cancer therapy: an historical perspective and an update

    Eur. J. Cancer

    (1998)
  • T. Ludwig et al.

    Nephrotoxicity of platinum complexes is related to basolateral organic cation transport

    Kidney Int.

    (2004)
  • R. Masereeuw et al.

    Therapeutic implications of renal anionic drug transporters

    Pharmacol. Ther.

    (2010)
  • M. Mishima et al.

    The cellular pharmacology of oxaliplatin resistance

    Eur. J. Cancer

    (2002)
  • J.L. Misset et al.

    Oxaliplatin clinical activity: a review

    Crit. Rev. Oncol. Hematol.

    (2000)
  • T. Nakamura et al.

    Disruption of multidrug and toxin extrusion MATE1 potentiates cisplatin-induced nephrotoxicity

    Biochem. Pharmacol.

    (2010)
  • Y. Nose et al.

    Structure of the Ctr1 copper trans’PORE’ter reveals novel architecture

    Trends Biochem. Sci.

    (2006)
  • H. Omote et al.

    The MATE proteins as fundamental transporters of metabolic and xenobiotic organic cations

    Trends Pharmacol. Sci.

    (2006)
  • E. Raymond et al.

    Oxaliplatin: a review of preclinical and clinical studies

    Ann. Oncol.

    (1998)
  • O. Rixe et al.

    Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen panel

    Biochem. Pharmacol.

    (1996)
  • R. Safaei

    Role of copper transporters in the uptake and efflux of platinum containing drugs

    Cancer Lett.

    (2006)
  • R. Safaei et al.

    The role of copper transporters in the development of resistance to Pt drugs

    J. Inorg. Biochem.

    (2004)
  • R. Safaei et al.

    Copper transporters regulate the cellular pharmacology and sensitivity to Pt drugs

    Crit. Rev. Oncol. Hematol.

    (2005)
  • M.M. Shahzad et al.

    Novel strategies for reversing platinum resistance

    Drug Resist. Updat.

    (2009)
  • B. Stordal et al.

    A systematic review of platinum and taxane resistance from bench to clinic: an inverse relationship

    Cancer Treat. Rev.

    (2007)
  • P.A. Andrews et al.

    Rapid emergence of acquired cis-diamminedichloroplatinum(II) resistance in an in vivo model of human ovarian carcinoma

    Cancer Commun.

    (1990)
  • A. Ardizzoni et al.

    Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis

    J. Natl. Cancer Inst.

    (2007)
  • B.G. Blair et al.

    Copper transporter 2 regulates the cellular accumulation and cytotoxicity of cisplatin and carboplatin

    Clin. Cancer Res.

    (2009)
  • P. Borst et al.

    How do real tumors become resistant to cisplatin?

    Cell Cycle

    (2008)
  • O. Briz et al.

    Carriers involved in targeting the cytostatic bile acid-cisplatin derivatives cis-diammine-chloro-cholylglycinate-platinum(II) and cis-diammine-bisursodeoxycholate-platinum(II) toward liver cells

    Mol. Pharmacol.

    (2002)
  • E. Buchdunger et al.

    Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors

    J. Pharmacol. Exp. Ther.

    (2000)
  • H. Burger et al.

    Pharmacokinetic resistance to imatinib mesylate: role of the ABC drug pumps ABCG2 (BCRP) and ABCB1 (MDR1) in the oral bioavailability of imatinib

    Cell Cycle

    (2004)
  • H. Burger et al.

    Chronic imatinib mesylate exposure leads to reduced intracellular drug accumulation by induction of the ABCG2 (BCRP) and ABCB1 (MDR1) drug transport pumps

    Cancer Biol. Ther.

    (2005)
  • H. Burger et al.

    Differential transport of platinum compounds by the human organic cation transporter hOCT2 (hSLC22A2)

    Br. J. Pharmacol.

    (2010)
  • W.L. Burland et al.

    Pharmacological evaluation of cimetidine, a new histamine H2-receptor antagonist, in healthy man

    Br. J. Clin. Pharmacol.

    (1975)
  • I. Buss et al.

    Influence of the hOCT2 inhibitor cimetidine on the cellular accumulation and cytotoxicity of oxaliplatin

    Int. J. Clin. Pharmacol. Ther.

    (2009)
  • Y. Chen et al.

    Genetic variants in multidrug and toxic compound extrusion-1, hMATE1, alter transport function

    Pharmacogenomics J.

    (2009)
  • M.K. Choi et al.

    Platinum transporters and drug resistance

    Arch. Pharm. Res.

    (2006)
  • H. Choy et al.

    Current status and future prospects for satraplatin, an oral platinum analogue

    Clin. Cancer Res.

    (2008)
  • S.P. Cole et al.

    Pharmacological characterization of multidrug resistant MRP-transfected human tumor cells

    Cancer Res.

    (1994)
  • M. Coluccia et al.

    Trans-platinum complexes in cancer therapy

    Anticancer Agents Med. Chem.

    (2007)
  • P.D. Dobson et al.

    Carrier-mediated cellular uptake of pharmaceutical drugs: an exception or the rule?

    Nat. Rev. Drug Discov.

    (2008)
  • P.D. Dobson et al.

    Implications of the dominant role of transporters in drug uptake by cells

    Curr. Top. Med. Chem.

    (2009)
  • J.R. Eckardt et al.

    Phase II study of picoplatin as second-line therapy for patients with small-cell lung cancer

    J. Clin. Oncol.

    (2009)
  • Eechoute, K., Sparreboom, A., Burger, H., Franke, R.M., Verweij, J., Loos, W.J., Wiemer, E.A.C., Mathijssen, R.H.J.,...
  • K.K. Filipski et al.

    Interaction of cisplatin with the human organic cation transporter 2

    Clin. Cancer Res.

    (2008)
  • K.K. Filipski et al.

    Contribution of organic cation transporter 2 (OCT2) to cisplatin-induced nephrotoxicity

    Clin. Pharmacol. Ther.

    (2009)
  • R.M. Franke et al.

    Influence of Oct1/Oct2-deficiency on cisplatin-induced changes in urinary N-acetyl-beta-d-glucosaminidase

    Clin. Cancer Res.

    (2010)
  • S. Fu et al.

    Clinical application of oxaliplatin in epithelial ovarian cancer

    Int. J. Gynecol. Cancer

    (2006)
  • Cited by (0)

    View full text